| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8453933 | Lung Cancer | 2018 | 5 Pages |
Abstract
A subset of patients with EGFR mutations or ALK rearrangements had a PD-L1 TPS of â¥50%. Prospective studies are thus warranted to examine the efficacy of PD-1/PD-L1 inhibitors in such patients.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Yasuto Yoneshima, Kayo Ijichi, Satoshi Anai, Keiichi Ota, Kohei Otsubo, Eiji Iwama, Kentaro Tanaka, Yoshinao Oda, Yoichi Nakanishi, Isamu Okamoto,